402 / 1498
•
HL became curable with the introduction of multi-agent chemo
•
ABVD associated with 65-70% PFS and 75-80% OS @5yrs
•
B.esc gave 15-20% better PFS and 10-15% better OS than ABVD
•
Treatment-related mortality and 2
nd
npl of BEACOPP similar to ABVD;
more hematotox and infertility
•
6xB.esc: tumour control 89%, OS 95%; PET-guided RT (HD15)
•
B.esc not to be used in pts >40 yrs and poor performance
•
Ongoing trials evaluate PET-guided strategies and combining BV with
ABVD (enhance efficacy) BEACOPP (reduce toxicity)
Advanced stage HL
Summary